EnQuest (LSE: ENQ) full-year 2025 results: Production up 5.4%, dividend raised as South East Asia pivot reshapes growth outlook
Can Southland Holdings, Inc. turn water and data center demand into a cleaner growth story? (NYSE American: SLND)
Read More 3 minute read Pharma Industry News RIBOMIC completes patient enrollment in early phase II study of umedaptanib pegol for Achondroplasia RIBOMIC Inc., a Tokyo-based leader in aptamer therapeutics, has reported significant progress in its early phase II study… byPallavi MadhirajuAugust 4, 2024